144.41
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$144.83
Offen:
$144.69
24-Stunden-Volumen:
899.39K
Relative Volume:
0.55
Marktkapitalisierung:
$21.85B
Einnahmen:
$4.39B
Nettoeinkommen (Verlust:
$853.00M
KGV:
26.21
EPS:
5.5097
Netto-Cashflow:
$556.00M
1W Leistung:
+1.31%
1M Leistung:
+10.66%
6M Leistung:
+16.60%
1J Leistung:
+79.30%
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ILMN
Illumina Inc
|
144.41 | 21.91B | 4.39B | 853.00M | 556.00M | 5.5097 |
|
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
|
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Illumina stock (US4523271090): institutional buying meets cautious analyst outlook - AD HOC NEWS
Illumina Summit Highlights Multi-Omics Potential in India - Deccan Chronicle
Illumina (NASDAQ: ILMN) director Susan Siegel receives 2,072-share RSU grant - Stock Titan
Illumina (ILMN) awards 2,072 restricted stock units to director - Stock Titan
Illumina (ILMN) director Scott B. Ullem receives 2,072-share RSU award - Stock Titan
Illumina (ILMN) director Philip Schiller receives 2,072-share restricted stock grant - Stock Titan
Illumina (ILMN) director Anna Richo granted 2,072 restricted stock units as equity pay - Stock Titan
Illumina (ILMN) director Keith Meister granted 2,072 RSUs and updates holdings - Stock Titan
Illumina (ILMN) director Scott Gottlieb receives 2,072-share RSU grant - Stock Titan
Illumina (ILMN) director David P. King submits initial Form 3 - Stock Titan
Illumina’s SWOT analysis: stock faces visibility concerns despite growth By Investing.com - Investing.com Canada
Illumina’s SWOT analysis: stock faces visibility concerns despite growth - Investing.com
Understanding Momentum Shifts in (ILMN) - Stock Traders Daily
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina adds former Labcorp CEO to board of directors By Investing.com - Investing.com Canada
David P. King elected to Illumina's Board of Directors - Illumina
ILMN: All proposals were preliminarily approved, with no questions raised during the Q&A session - TradingView
DNA Methylation Sequencing Market to Reach USD 5.49 Billion - openPR.com
NGS-Based RNA Sequencing Market to Reach USD 15.0 Billion by 2033 - openPR.com
Illumina stock (US4523271090): corporate responsibility push after return to growth - AD HOC NEWS
Illumina stock (US4523271090): Corporate Responsibility Report highlights genomics growth drivers - AD HOC NEWS
Is This the Right Time to Retain ILMN Stock in Your Portfolio? - Yahoo Finance
Illumina stock (US4523271090): new responsibility report highlights growth drivers in genomics - AD HOC NEWS
Earnings Beat, Buyback, China Signals Might Change The Case For Investing In Illumina (ILMN) - Yahoo Finance
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact - PR Newswire
SomaLogic Inc stock (US82489T1043): Illumina takeover reshapes proteomics story - AD HOC NEWS
Illumina stock (US4523271090): analysts see limited upside after volatile Nasdaq recovery - AD HOC NEWS
Illumina price tries to vent off overbought saturationForecast today18-05-2026 - Economies.com
NXP, Illumina, StoneX Group: Momentum Stocks Analysis (Buy & Sell)May 2026News and Statistics - IndexBox
Illumina stock (US4523271090): analysts see limited upside after recent volatility - AD HOC NEWS
Illumina stock (US4523271090): analysts see limited upside after volatile trading - AD HOC NEWS
Illumina Inc stock (US4523271090): spin-off progress and earnings keep investors alert - AD HOC NEWS
Illumina, Inc. Trade Ideas — EUROTLX:4ILMN - TradingView
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story - AD HOC NEWS
Illumina Inc stock (US4523271090): gene sequencing player in focus after latest earnings and divesti - AD HOC NEWS
Illumina's new connected multiomics platform set to boost its stock - MSN
Illumina CEO Joins Trump-Xi Summit: Here’s What It Means for ILMN Stock - TIKR.com
MFS Blended Research Mid Cap Equity Fund's Illumina Inc(ILMN) Holding History - GuruFocus
Illumina, Inc.Common Stock (Nasdaq:ILMN) Stock Quote - FinancialContent
Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says - Moomoo
Swiss Life Asset Management Ltd Sells 47,498 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Insider Sold Shares Worth $47,931,975, According to a Recent SEC Filing - marketscreener.com
Illumina stock (US4523271090): gene sequencing player in focus after leadership and strategy updates - AD HOC NEWS
RBC Capital Mkts resumed coverage on Illumina with a new price target - Quantisnow
Is Illumina (ILMN) Pricing Look Interesting After 77% One Year Share Price Gain - Yahoo Finance
Illumina (ILMN) Coverage Resumed with Outperform Rating and $170 Target - GuruFocus
Illumina director Keith Meister sells $47.9m in shares - Investing.com India
Illumina director Keith Meister sells $47.9m in shares By Investing.com - Investing.com Nigeria
Illumina(ILMN.US) Director Sells US$47.93 Million in Common Stock - Moomoo
Corvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps - Stock Titan
RBC Capital assumes Illumina stock coverage with outperform rating By Investing.com - Investing.com Australia
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Illumina Inc-Aktie (ILMN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Meister Keith A. | Director |
May 14 '26 |
Sale |
145.34 |
104,393 |
15,172,381 |
3,500,048 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):